Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up – Time to Buy?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG)’s stock price gapped up before the market opened on Friday . The stock had previously closed at $23.20, but opened at $27.54. Ascentage Pharma Group International shares last traded at $27.54, with a volume of 1,685 shares.

Wall Street Analysts Forecast Growth

Several analysts have commented on AAPG shares. Piper Sandler assumed coverage on shares of Ascentage Pharma Group International in a research report on Wednesday, November 5th. They set an “overweight” rating and a $48.00 target price for the company. Rodman & Renshaw began coverage on Ascentage Pharma Group International in a research note on Tuesday, January 13th. They issued a “buy” rating and a $48.00 target price on the stock. Truist Financial set a $51.00 target price on Ascentage Pharma Group International in a research report on Monday, November 24th. Lucid Cap Mkts raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, December 15th. Finally, BTIG Research assumed coverage on shares of Ascentage Pharma Group International in a research report on Monday, November 10th. They set a “buy” rating and a $50.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the stock. Based on data from MarketBeat.com, Ascentage Pharma Group International currently has a consensus rating of “Buy” and an average target price of $48.40.

Ascentage Pharma Group International Price Performance

The stock has a fifty day simple moving average of $26.73 and a 200-day simple moving average of $33.69. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.53 and a current ratio of 1.54.

Hedge Funds Weigh In On Ascentage Pharma Group International

Hedge funds have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Ascentage Pharma Group International in the third quarter worth $96,000. ABC Arbitrage SA acquired a new stake in Ascentage Pharma Group International in the 3rd quarter valued at $204,000. Chevy Chase Trust Holdings LLC bought a new stake in Ascentage Pharma Group International during the 2nd quarter worth about $227,000. Citadel Advisors LLC acquired a new position in shares of Ascentage Pharma Group International during the 3rd quarter worth about $383,000. Finally, Hsbc Holdings PLC bought a new position in shares of Ascentage Pharma Group International in the 2nd quarter valued at about $391,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.